Jazz Financial Statements From 2010 to 2024
| J7Z Stock | EUR 116.85 1.15 0.97% |
Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
Jazz |
Jazz Pharmaceuticals plc Company Return On Asset Analysis
Jazz Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Jazz Pharmaceuticals Return On Asset | 0.053 |
Most of Jazz Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Jazz Pharmaceuticals plc has a Return On Asset of 0.053. This is 100.61% lower than that of the Healthcare sector and 100.22% lower than that of the Biotechnology industry. The return on asset for all Germany stocks is 137.86% lower than that of the firm.
Jazz Pharmaceuticals plc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Jazz Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Jazz Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Jazz Pharmaceuticals competition to find correlations between indicators driving Jazz Pharmaceuticals's intrinsic value. More Info.Jazz Pharmaceuticals plc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Jazz Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Jazz Pharmaceuticals Financial Statements
Jazz Pharmaceuticals stakeholders use historical fundamental indicators, such as Jazz Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Jazz Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Jazz Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Jazz Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Jazz Pharmaceuticals plc. Please read more on our technical analysis and fundamental analysis pages.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc. Codiak BioSciences, Inc. Pfenex, Inc. and XL-protein GmbH. JAZZ PHARMACEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1460 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out the analysis of Jazz Pharmaceuticals Correlation against competitors. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.